{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:17:37Z","timestamp":1788261457941,"version":"build-2803163510"},"reference-count":37,"publisher":"IOP Publishing","issue":"35","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/publishingsupport.iopscience.iop.org\/iop-standard\/v1"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/iopscience.iop.org\/info\/page\/text-and-data-mining"}],"funder":[{"name":"Tianjin Health Research Project","award":["TJWJ2024QN050"],"award-info":[{"award-number":["TJWJ2024QN050"]}]},{"name":"Peking University First Hospital Research Seed Fund","award":["2023SF38"],"award-info":[{"award-number":["2023SF38"]}]}],"content-domain":{"domain":["iopscience.iop.org"],"crossmark-restriction":false},"short-container-title":["Nanotechnology"],"published-print":{"date-parts":[[2026,9,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Chemotherapy remains the primary treatment for most patients with metastatic colorectal cancer (mCRC), yet its efficacy is often limited by severe adverse effects. Drug repurposing offers a promising strategy to accelerate oncology drug development. Disulfiram (DSF), a licensed anti-alcoholism agent, has demonstrated broad-spectrum anticancer activity in preclinical models. However, its clinical translation for oncology is hindered by poor aqueous solubility, rapid metabolism, and lack of tumor selectivity. To overcome these limitations, we developed a novel targeted drug delivery system (Apt-NPs-DSF) by encapsulating disulfiram (DSF) within albumin nanoparticles (NPs) functionalized with the nucleolin-targeting AS1411 aptamer. Apt-NPs-DSF had an average size of 96.4 \u00b1 7.4 nm and was negatively charged with a zeta potential of \u221219.1 \u00b1 2.2 mV. Furthermore, DSF was released from the albumin NPs with a typical sustained release profile. Apt-NPs-DSF demonstrated favorable serum stability and hemocompatibility. Of note, aptamer-guided NPs were preferentially internalized by nucleolin-expressing CT26 colon cancer cells vs control cells. Moreover,\n                    <jats:italic>in vitro<\/jats:italic>\n                    cytotoxicity assay revealed that Apt-NPs-DSF significantly enhanced the killing of CT26 colon cancer cells. Importantly,\n                    <jats:italic>in vivo<\/jats:italic>\n                    study confirmed that Apt-NPs-DSF achieved superior antitumor efficacy without raising systemic toxicity, outperforming non-targeted counterparts. Collectively, these results suggest that Apt-NPs-DSF has potential in the targeted treatment of colon cancer.\n                  <\/jats:p>","DOI":"10.1088\/1361-6528\/ae9b13","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T22:48:13Z","timestamp":1787093293000},"page":"355101","update-policy":"https:\/\/doi.org\/10.1088\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted therapy of colon cancer with aptamer-functionalized albumin nanoparticles loaded with disulfiram"],"prefix":"10.1088","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1532-0751","authenticated-orcid":true,"given":"Yacong","family":"An","sequence":"first","affiliation":[{"name":"Biobank of Peking University First Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6200-0944","authenticated-orcid":true,"given":"Zhen","family":"Yu","sequence":"additional","affiliation":[{"name":"Tianjin Third Central Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xundou","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiping","family":"Jiang","sequence":"additional","affiliation":[{"name":"Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"266","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"nanoae9b13bib1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","type":"journal-article","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"nanoae9b13bib2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.clcc.2022.05.006","type":"journal-article","article-title":"Clinical updates for colon cancer care in 2022","volume":"21","author":"Fabregas","year":"2022","journal-title":"Clin. Colorectal Cancer"},{"key":"nanoae9b13bib3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102676","type":"journal-article","article-title":"Neoadjuvant chemotherapy for early-stage colon cancer","volume":"123","author":"Audisio","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"nanoae9b13bib4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1055\/s-0045-1802564","type":"journal-article","article-title":"The adjuvant treatment of stage III colon cancer: might less be more?","volume":"32","author":"Lee","year":"2018","journal-title":"Oncology"},{"key":"nanoae9b13bib5","doi-asserted-by":"publisher","first-page":"6070","DOI":"10.1158\/1078-0432.CCR-09-1035","type":"journal-article","article-title":"High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth","volume":"15","author":"Iljin","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"nanoae9b13bib6","doi-asserted-by":"publisher","first-page":"10425","DOI":"10.1158\/0008-5472.CAN-06-2126","type":"journal-article","article-title":"Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity","volume":"66","author":"Chen","year":"2006","journal-title":"Cancer Res."},{"key":"nanoae9b13bib7","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.1158\/0008-5472.CAN-13-3527","type":"journal-article","article-title":"Copper signaling axis as a target for prostate cancer therapeutics","volume":"74","author":"Safi","year":"2014","journal-title":"Cancer Res."},{"key":"nanoae9b13bib8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.4149","type":"journal-article","article-title":"Effect of disulfiram and copper plus chemotherapy vs chemotherapy alone on survival in patients with recurrent glioblastoma: a randomized clinical trial","volume":"6","author":"Werlenius","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"nanoae9b13bib9","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/pros.24329","type":"journal-article","article-title":"Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer","volume":"82","author":"Zhang","year":"2022","journal-title":"Prostate"},{"key":"nanoae9b13bib10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087366","type":"journal-article","article-title":"Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis","volume":"9","author":"Skinner","year":"2014","journal-title":"PLoS One"},{"key":"nanoae9b13bib11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nature25016","type":"journal-article","article-title":"Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4","volume":"552","author":"Skrott","year":"2017","journal-title":"Nature"},{"key":"nanoae9b13bib12","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121335","type":"journal-article","article-title":"Leveraging disulfiram to treat cancer: mechanisms of action, delivery strategies, and treatment regimens","volume":"281","author":"Lu","year":"2022","journal-title":"Biomaterials"},{"key":"nanoae9b13bib13","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ijbiomac.2022.01.145","type":"journal-article","article-title":"Fabrication, characterization and in vitro evaluation of disulfiram-loaded cellulose acetate\/poly(ethylene oxide) nanofiber scaffold for breast and colon cancer cell lines treatment","volume":"204","author":"El Fawal","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"nanoae9b13bib14","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jhep.2005.12.016","type":"journal-article","article-title":"Clinical characteristics and prognostic markers in disulfiram-induced liver injury","volume":"44","author":"Bjornsson","year":"2006","journal-title":"J. Hepatol."},{"key":"nanoae9b13bib15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13256-016-0865-z","type":"journal-article","article-title":"Disulfiram neuropathy: two case reports","volume":"10","author":"Tran","year":"2016","journal-title":"J. Med. Case Rep."},{"key":"nanoae9b13bib16","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ejpb.2016.11.032","type":"journal-article","article-title":"Development and characterisation of disulfiram-loaded PLGA nanoparticles for the treatment of non-small cell lung cancer","volume":"112","author":"Najlah","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"nanoae9b13bib17","doi-asserted-by":"publisher","first-page":"6737","DOI":"10.2147\/IJN.S267177","type":"journal-article","article-title":"Targeted treatment of colon cancer with aptamer-guided albumin nanoparticles loaded with docetaxel","volume":"15","author":"Yu","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"nanoae9b13bib18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.colsurfb.2016.05.051","type":"journal-article","article-title":"Fucose decorated solid-lipid nanocarriers mediate efficient delivery of methotrexate in breast cancer therapeutics","volume":"146","author":"Garg","year":"2016","journal-title":"Colloids Surf. B"},{"key":"nanoae9b13bib19","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.3892\/or.2018.6201","type":"journal-article","article-title":"Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptor 2\u2013positive gastric cancer","volume":"39","author":"Xiong","year":"2018","journal-title":"Oncol. Rep."},{"key":"nanoae9b13bib20","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1080\/17425247.2016.1193149","type":"journal-article","article-title":"Albumin nanostructures as advanced drug delivery systems","volume":"13","author":"Karimi","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"nanoae9b13bib21","doi-asserted-by":"publisher","first-page":"7515","DOI":"10.1007\/s00432-023-04698-y","type":"journal-article","article-title":"Novel nanotherapeutics for cancer immunotherapy by CTLA-4 aptamer-functionalized albumin nanoparticle loaded with antihistamine","volume":"149","author":"Yao","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"nanoae9b13bib22","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.7150\/thno.19365","type":"journal-article","article-title":"Strategies for preparing albumin-based nanoparticles for multifunctional bioimaging and drug delivery","volume":"7","author":"An","year":"2017","journal-title":"Theranostics"},{"key":"nanoae9b13bib23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3892\/ijo.2022.5355","type":"journal-article","article-title":"Aptamer\u2010based therapy for targeting key mediators of cancer metastasis (Review)","volume":"60","author":"Alhamhoom","year":"2022","journal-title":"Int. J. Oncol."},{"key":"nanoae9b13bib24","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","type":"journal-article","article-title":"FDA-approved oligonucleotide therapies in 2017","volume":"25","author":"Stein","year":"2017","journal-title":"Mol. Ther."},{"key":"nanoae9b13bib25","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.ijbiomac.2019.11.118","type":"journal-article","article-title":"Therapeutic applications of AS1411 aptamer, an update review","volume":"155","author":"Yazdian-robati","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"nanoae9b13bib26","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202101707","type":"journal-article","article-title":"Secreted expression of mRNA-encoded truncated ACE2 variants for SARS-CoV-2 via lipid-like nanoassemblies","volume":"33","author":"Li","year":"2021","journal-title":"Adv. Mater."},{"key":"nanoae9b13bib27","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1208\/s12249-021-02108-5","type":"journal-article","article-title":"Primaquine loaded solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and nanoemulsion (NE): effect of lipid matrix and surfactant on drug entrapment, in vitro release, and ex vivo hemolysis","volume":"22","author":"Wu","year":"2021","journal-title":"AAPS PharmSciTech"},{"key":"nanoae9b13bib28","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.2147\/IJN.S25175","type":"journal-article","article-title":"Intramyocardial sustained delivery of placental growth factor using nanoparticles as a vehicle for delivery in the rat infarct model","volume":"6","author":"Binsalamah","year":"2011","journal-title":"Int. J. Nanomed"},{"key":"nanoae9b13bib29","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/cas.15650","type":"journal-article","article-title":"Pembrolizumab in Asian patients with microsatellite-instability-high\/mismatch-repair-deficient colorectal cancer","volume":"114","author":"Yoshino","year":"2023","journal-title":"Cancer Sci."},{"key":"nanoae9b13bib30","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1056\/NEJMc1510353","type":"journal-article","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"373","author":"Asaoka","year":"2015","journal-title":"New. Engl. J. Med."},{"key":"nanoae9b13bib31","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","type":"journal-article","article-title":"Treatment of metastatic colorectal cancer: ASCO guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"nanoae9b13bib32","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.drudis.2011.12.010","type":"journal-article","article-title":"Nonprofit drugs as the salvation of the world\u2019s healthcare systems: the case of Antabuse (disulfiram)","volume":"17","author":"Cvek","year":"2012","journal-title":"Drug Discov. Today"},{"key":"nanoae9b13bib33","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ijpharm.2018.12.051","type":"journal-article","article-title":"Integrating the drug, disulfiram into the vitamin E-TPGS-modified PEGylated nanostructured lipid carriers to synergize its repurposing for anti-cancer therapy of solid tumors","volume":"557","author":"Banerjee","year":"2019","journal-title":"Int. J. Pharm."},{"key":"nanoae9b13bib34","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2020.111452","type":"journal-article","article-title":"Disulfiram-loaded functionalized magnetic nanoparticles combined with copper and sodium nitroprusside in breast cancer cells","volume":"119","author":"Solak","year":"2021","journal-title":"Mater. Sci. Eng. C"},{"key":"nanoae9b13bib35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40591-016-0048-8","type":"journal-article","article-title":"Albumin-based drug delivery: harnessing nature to cure disease","volume":"4","author":"Larsen","year":"2016","journal-title":"Mol. Cell Ther."},{"key":"nanoae9b13bib36","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s10637-013-0045-6","type":"journal-article","article-title":"A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma","volume":"32","author":"Rosenberg","year":"2014","journal-title":"Invest. New Drugs"},{"key":"nanoae9b13bib37","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1158\/1535-7163.MCT-06-0172","type":"journal-article","article-title":"Discovery and development of anticancer aptamers","volume":"5","author":"Ireson","year":"2006","journal-title":"Mol. Cancer Ther."}],"container-title":["Nanotechnology"],"original-title":[],"link":[{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6528\/ae9b13","content-type":"text\/html","content-version":"am","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6528\/ae9b13\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6528\/ae9b13","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6528\/ae9b13\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6528\/ae9b13\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6528\/ae9b13\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6528\/ae9b13\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"similarity-checking"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6528\/ae9b13\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:41:44Z","timestamp":1788259304000},"score":1,"resource":{"primary":{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6528\/ae9b13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":37,"journal-issue":{"issue":"35","published-online":{"date-parts":[[2026,9,1]]},"published-print":{"date-parts":[[2026,9,4]]}},"URL":"https:\/\/doi.org\/10.1088\/1361-6528\/ae9b13","relation":{},"ISSN":["0957-4484","1361-6528"],"issn-type":[{"value":"0957-4484","type":"print"},{"value":"1361-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"Targeted therapy of colon cancer with aptamer-functionalized albumin nanoparticles loaded with disulfiram","name":"article_title","label":"Article Title"},{"value":"Nanotechnology","name":"journal_title","label":"Journal Title"},{"value":"paper","name":"article_type","label":"Article Type"},{"value":"\u00a9 2026 IOP Publishing Ltd. All rights, including for text and data mining, AI training, and similar technologies, are reserved.","name":"copyright_information","label":"Copyright Information"},{"value":"2026-04-23","name":"date_received","label":"Date Received","group":{"name":"publication_dates","label":"Publication dates"}},{"value":"2026-08-18","name":"date_accepted","label":"Date Accepted","group":{"name":"publication_dates","label":"Publication dates"}},{"value":"2026-09-01","name":"date_epub","label":"Online publication date","group":{"name":"publication_dates","label":"Publication dates"}}]}}